Showing results (41-50 of 104) with videos related to
Sort By:
Pageof 11
Annals of Hematology|October 26, 2013
GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphomaEliza A Hawkes, Sarah Barton, David Cunningham, et al.Ejhaem|July 18, 2022
Whole body-diffusion weighted imaging for the assessment of treatment response in hairy cell leukaemia: A positive first stepAshwin Algudkar, Dima El-Sharkawi, Matthew Cross, et al.British Journal of Sports Medicine|February 12, 2021
SARS-CoV-2 transmission during rugby league matches: do players become infected after participating with SARS-CoV-2 positive players?Ben Jones, Gemma Phillips, Simon Kemp, et al.Journal of Medicinal Chemistry|November 25, 2011
Synthesis, antimalarial activity, and structure-activity relationship of 7-(2-phenoxyethoxy)-4(1H)-quinolonesR Matthew Cross, Niranjan K Namelikonda, Tina S Mutka, et al.British Journal of Sports Medicine|June 24, 2017
Risk factors for head injury events in professional rugby union: a video analysis of 464 head injury events to inform proposed injury prevention strategiesRoss Tucker, Martin Raftery, Simon Kemp, et al.Journal of Medicinal Chemistry|September 11, 2010
Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activityR Matthew Cross, Andrii Monastyrskyi, Tina S Mutka, et al.Leukemia & Lymphoma|December 10, 2016
Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013Mary Gleeson, Eliza A Hawkes, Clare Peckitt, et al.European Journal of Haematology|July 22, 2014
Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphomaSarah Barton, Eliza A Hawkes, David Cunningham, et al.The International Journal of Medical Robotics + Computer Assisted Surgery : MRCAS|April 30, 2021
Robotic surgery for colorectal cancer in the OctogenariansGal Westrich, Ioannis Mykoniatis, Samuel Stefan, et al.British Journal of Haematology|December 30, 2016
Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidationAbraham M Varghese, Dena R Howard, Christopher Pocock, et al.Pageof 11